Log In Get Started
Press Releases August 6, 2026 05:15 PM

LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

LeMaitre Vascular to Present at the 11th Annual Needham Virtual MedTech & Diagnostics Conference

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
LMAT

LeMaitre Vascular, a medical device company specializing in peripheral vascular disease treatment, will participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference, engaging with investors to discuss its products and market strategies.

LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
LMAT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • LeMaitre Vascular manufactures devices primarily for vascular surgeons treating peripheral vascular disease.
  • The company is participating in a major virtual investor conference targeting the MedTech and diagnostics sector.
  • Peripheral vascular disease affects over 200 million people worldwide, indicating a large potential market for LeMaitre's products.

BURLINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will hold investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 11, 2026.

About LeMaitre

LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com.

Contact:
Sandra Millar
LeMaitre Vascular, Inc.
+1-781-425-1686
smillar@lemaitre.com


Risks

  • The success of LeMaitre's market engagement depends on investor reception at the conference, which is uncertain.
  • Peripheral vascular disease treatment is a competitive market with evolving technologies and regulatory challenges.
  • Market acceptance and reimbursement policies for their vascular devices could impact future revenues.

More from Press Releases

HII is Awarded Long-Lead Time Materials Contract for CVN 82 Sep 11, 2026 FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S. Sep 11, 2026 Greenland Mines Provides Progress Update on 2026 Field Programs at Skaergaard and Sarfartoq Sep 11, 2026 Vicor acquires sites for additional ChiP fabs Sep 11, 2026 DoubleDown Interactive to Donate $10,000 to the ASPCA® Sep 11, 2026